In vitro and in vivo analysis of IgG antibody response against 47 kDa immunogenic protein from salivary gland of Aedes albopictus
DOI:
https://doi.org/10.24252/bio.v13i1.55036Keywords:
47 kDa immunogenic protein, Ae. Albopictus, IgG antibody, salivary glandAbstract
Dengue Hemorrhagic Fever (DHF) is a disease caused by the dengue virus. The virus is transmitted to humans through the blood-feeding activity of Aedes albopictus. This transmission is facilitated by specific proteins of salivary glands mosquito. Based on the previous studies, there are three immunogenic proteins were detected from salivary glands of Ae. albopictus, i.e 31, 47, and 67 kDa. The 47 kDa protein is one of the proteins suspected to be a serpin protein. These proteins are capable of inducing an immune response in the host. This study aims to assess the capacity of the 47 kDa immunogenic protein derived from the salivary glands of Ae. albopictus to elicit host immune responses. This is achieved through IgG analysis conducted both in vitro and in vivo analysis. In vitro IgG antibody response analysis was performed on human serum samples from healthy people, DHF patients and neonates collected from Jember. In vivo IgG antibody response analysis was performed on mice (Mus musculus) that had been injected with 47 kDa protein. IgG level measurement using the ELISA indirect method. According to in vitro examination of IgG antibody response in human samples against 47 kDa salivary protein, the highest IgG levels were detected in healthy samples followed by dengue patients and neonates. This suggests that the 47 kDa protein from Ae. albopictus salivary glands is recognized by human serum and developed into a biomarker for mosquito bites. In vivo examination of the IgG antibody response in mice (M. musculus) injected by 47 kDa protein revealed that the IgG antibody might be increased by repeated exposure to 47 kDa protein. The highest IgG level was detected in the 6th week after repeated exposure. Repeated exposure of the 47 kDa salivary protein from Ae. albopictus have been demonstrated to elicit a humoral immune response in mice.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Rike Oktarianti, Istiqomah Rizki Amalia, Shafira Firdausi, Syubbanul Wathon, Kartika Senjarini
This work is licensed under a Creative Commons Attribution 4.0 International License.
COPYRIGHT AND LICENSE STATEMENT
COPYRIGHT
Biogenesis: Jurnal Ilmiah Biologi is published under the terms of the Creative Commons Attribution license. Authors hold the copyright and retain publishing rights without restriction to their work. Users may read, download, copy, distribute, and print the work in any medium, provided the original work is properly cited.
LICENSE TO PUBLISH
1. License
The use of the article will be governed by the Creative Commons Attribution license as currently displayed on http://creativecommons.org/licenses/by/4.0.
2. Author’s Warranties
The author warrants that the article is original, written by stated author/s, has not been published before, contains no unlawful statements, does not infringe the rights of others, is subject to copyright that is vested exclusively in the author and free of any third party rights, and that any necessary written permissions to quote from other sources have been obtained by the author(s).
3. User Rights
Under the Creative Commons Attribution license, the users are free to download, reuse, reprint, modify, distribute and/or copy the content for any purpose, even commercially, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
4. Co-Authorship
If the article was prepared jointly with other authors, the corresponding author warrants that he/she has been authorized by all co-authors, and agrees to inform his/her co-authors of the terms of this statement.
5. Miscellaneous
Biogenesis: Jurnal Ilmiah Biologi may conform the article to a style of punctuation, spelling, capitalization, and usage that it deems appropriate. The author acknowledges that the article may be published so that it will be publicly accessible and such access will be free of charge for the readers.
